survivin/p53/HER2 antigen-loaded autologous dendritic cell vaccine
Term · Oncology and biomedicine · MLC-T-ONC-016924
An autologous dendritic cell (DC) vaccine loaded with tumor-associated antigens (TAAs) derived from survivin, p53 and human epidermal growth factor receptor 2 (HER2 or ERBB2), with immunostimulating and antineoplastic activities. Upon administration, this DC vaccine may elicit a potent cytotoxic T-cell (CTL) response against tumor cells expressing these TAAs, resulting in tumor cell death. Survivin, p53 and HER2 are essential in neoplastic growth, and are considered to be universal tumor antigens.
| Identifier | MLC-T-ONC-016924 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | survivin/p53/HER2 antigen-loaded autologous DC vaccine |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-016924",
"term": "survivin/p53/HER2 antigen-loaded autologous dendritic cell vaccine",
"field": "Oncology and biomedicine",
"definition": "An autologous dendritic cell (DC) vaccine loaded with tumor-associated antigens (TAAs) derived from survivin, p53 and human epidermal growth factor receptor 2 (HER2 or ERBB2), with immunostimulating and antineoplastic activities. Upon administration, this DC vaccine may elicit a potent cytotoxic T-cell (CTL) response against tumor cells expressing these TAAs, resulting in tumor cell death. Survivin, p53 and HER2 are essential in neoplastic growth, and are considered to be universal tumor antigens.",
"synonyms": [
"survivin/p53/HER2 antigen-loaded autologous DC vaccine"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/survivin-p53-her2-antigen-loaded-autologous-dendritic-cell-vaccine/"
}
Record 15,835 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.